ArticleRMD open2026
Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study.
Article in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)-driven in part by chronic inflammation-and is linked to a poor prognosis. This study aimed to investigate the prevalence of sarcopenia in patients with RA using Asian Working Group for Sarcopenia (AWGS) 2025 criteria and to analyse its associated clinical features.
methodsThis cross-sectional study enrolled 978 patients with RA (mean age 60.1±12.1 years, range 21-99 years and 86.4% female) diagnosed according to the 2010 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria. Sarcopenia was diagnosed based on the AWGS 2025 consensus, using bioelectrical impedance analysis for appendicular skeletal muscle mass index, handgrip dynamometry for muscle strength. Demographic data, clinical parameters and medication use were collected. Statistical analysis was performed using SPSS V.21.0.
resultsThe overall prevalence of sarcopenia among patients with RA was 18.6% (182/978). Male gender (OR 9.140, 95% CI 5.211 to 16.029), body mass index (BMI) (OR 0.586, 95% CI 0.534 to 0.643), disease duration (OR 1.046, 95% CI 1.025 to 1.069), rheumatoid factor (RF)-IgM level (OR 1.002, 95% CI 1.000 to 1.003), prednisone dosage (OR 1.094, 95% CI 1.033 to 1.159), tumour necrosis factor inhibitors (TNF-i) use (OR 0.502, 95% CI 0.312 to 0.808) and tocilizumab use (OR 0.493, 95% CI 0.304 to 0.799) were associated with sarcopenia in patients with RA.
conclusionThe prevalence of sarcopenia is considerable in patients with RA. Key risk factors include male gender, lower BMI, longer disease duration, higher RF-IgM level and higher dosage of glucocorticoid use. The use of tocilizumab and TNF-i may be associated with a reduced incidence of sarcopenia in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.